Billionaire Patrick Soon-Shiong Leads $75 Million Round in Multiply Labs

Patrick Soon-Shiong leads a $75 million funding round in Multiply Labs, according to a report by Billionaires.Africa. The deal puts one of the world's best-known billionaire healthcare entrepreneurs at the head of a nine-figure financing for a company operating at the intersection of automation and life sciences.

The figure is the hardest fact in the story: $75 million. The lead investor is Patrick Soon-Shiong. The recipient is Multiply Labs. Everything else in the transaction — the full investor syndicate, the valuation attached to the round, and the intended use of proceeds — remains outside the details carried in the report, and market watchers will fill those gaps only as the company or its backers disclose them.

Who is Patrick Soon-Shiong?

Soon-Shiong is a surgeon, scientist and businessman who built his fortune in pharmaceuticals and biotechnology. He is the figure the report names as leading the round. His participation matters for a simple reason: when an investor of his standing tops a financing, the market reads it as a signal about where he sees durable commercial opportunity.

The Billionaires.Africa report identifies him as the lead of the $75 million round. No quote from Soon-Shiong accompanies the report, and no co-investors are named in the published item.

What does the deal signal?

A $75 million round is a substantial commitment by any measure. For Multiply Labs, the financing provides fresh capital from a backer with deep experience in medicine, drug development and large-scale healthcare businesses.

The deal also extends a broader pattern: billionaire founders and operators increasingly anchor private rounds directly rather than delegating allocation to funds. Soon-Shiong's lead position puts his own capital and reputation behind Multiply Labs.

According to the Billionaires.Africa report:

• The round totals $75 million.
• Patrick Soon-Shiong leads the financing.
• Multiply Labs is the recipient company.

Why does the lead investor's identity matter?

In private markets, the identity of a lead investor often carries as much information as the check size. A lead sets terms, takes the largest allocation and typically takes a governance role. Soon-Shiong's name at the top of this round tells founders, employees and future investors that the financing cleared his diligence.

The report does not state a post-money valuation, a share class, or a board seat. Those terms, standard in rounds of this scale, stay private for now.

What comes next?

The $75 million gives Multiply Labs capital to deploy on the timeline its leadership chooses. Whether the company uses it to scale operations, expand its technology, or extend its commercial reach will become clear in subsequent disclosures.

For the wider market, the transaction adds a data point to 2025's funding record: capital remains available at size for companies that win the backing of proven operators. The next signal to watch is whether Multiply Labs or Soon-Shiong discloses the round's remaining participants, the valuation, or the strategic rationale — details that would let outside observers price what the billionaire's lead position already implies.